688443 智翔金泰-U
已收盘 07-10 15:00:02
资讯
新帖
简况
每周股票复盘：智翔金泰（688443）撤回特应性皮炎药注册申请
证券之星 · 07-05
每周股票复盘：智翔金泰（688443）撤回特应性皮炎药注册申请
智翔金泰（688443）披露关于撤回药品注册申请的公告，7月01日股价上涨4.43%
证券之星 · 07-01
智翔金泰（688443）披露关于撤回药品注册申请的公告，7月01日股价上涨4.43%
股市必读：智翔金泰（688443）6月26日董秘有最新回复
证券之星 · 06-29
股市必读：智翔金泰（688443）6月26日董秘有最新回复
智翔金泰（688443）2671万股限售股将于6月24日解禁，占总股本7.28%
证券之星 · 06-24
智翔金泰（688443）2671万股限售股将于6月24日解禁，占总股本7.28%
智翔金泰（688443）披露斯乐韦米单抗注射液获批上市，6月22日股价下跌2.56%
证券之星 · 06-22
智翔金泰（688443）披露斯乐韦米单抗注射液获批上市，6月22日股价下跌2.56%
智翔金泰(688443.SH)：狂犬病被动免疫制剂“斯乐韦米单抗注射液”获批上市
智通财经 · 06-22
智翔金泰(688443.SH)：狂犬病被动免疫制剂“斯乐韦米单抗注射液”获批上市
股市必读：智翔金泰（688443）6月18日董秘有最新回复
证券之星 · 06-22
股市必读：智翔金泰（688443）6月18日董秘有最新回复
每周股票复盘：智翔金泰（688443）部分限售股将上市流通
证券之星 · 06-20
每周股票复盘：智翔金泰（688443）部分限售股将上市流通
智翔金泰（688443）披露首次公开发行部分限售股上市流通公告，6月16日股价下跌2.26%
证券之星 · 06-16
智翔金泰（688443）披露首次公开发行部分限售股上市流通公告，6月16日股价下跌2.26%
智翔金泰2671万股即将解禁 分析师称属正常市场行为
中金财经 · 06-15
智翔金泰2671万股即将解禁 分析师称属正常市场行为
每周股票复盘：智翔金泰（688443）2025年度股东会审议通过多项议案
证券之星 · 06-07
每周股票复盘：智翔金泰（688443）2025年度股东会审议通过多项议案
每周股票复盘：智翔金泰（688443）GR1803项目获3亿首付款
证券之星 · 05-31
每周股票复盘：智翔金泰（688443）GR1803项目获3亿首付款
智翔金泰（688443）披露GR1803项目许可协议，5月28日股价下跌0.81%
证券之星 · 05-28
智翔金泰（688443）披露GR1803项目许可协议，5月28日股价下跌0.81%
A股公告精选 | 中芯国际(00981)、沪硅产业(688126.SH)等近期遭国家大基金减持
智通财经网 · 05-28
A股公告精选 | 中芯国际(00981)、沪硅产业(688126.SH)等近期遭国家大基金减持
复星医药子公司药友制药与智翔金泰签署许可协议，潜在首付款及里程碑付款总额高达6亿元
美股速递 · 05-28
复星医药子公司药友制药与智翔金泰签署许可协议，潜在首付款及里程碑付款总额高达6亿元
复星医药宣布智翔金泰授予药友集团抗体药物产品大中华区独家开发、商业化及生产权
美股速递 · 05-28
复星医药宣布智翔金泰授予药友集团抗体药物产品大中华区独家开发、商业化及生产权
智翔金泰(688443.SH)与药友制药就GR1803项目签署许可协议 总金额至高18.2亿元
智通财经 · 05-28
智翔金泰(688443.SH)与药友制药就GR1803项目签署许可协议 总金额至高18.2亿元
每周股票复盘：智翔金泰（688443）GR1803获临床试验批准
证券之星 · 05-17
每周股票复盘：智翔金泰（688443）GR1803获临床试验批准
智翔金泰(688443.SH)在研产品GR1803注射液(皮下注射)临床试验申请获批
智通财经 · 05-14
智翔金泰(688443.SH)在研产品GR1803注射液(皮下注射)临床试验申请获批
智翔金泰（688443）披露召开2025年年度暨2026年第一季度业绩说明会公告，5月13日股价下跌1.12%
证券之星 · 05-13
智翔金泰（688443）披露召开2025年年度暨2026年第一季度业绩说明会公告，5月13日股价下跌1.12%
暂无数据
公司概况
公司名称：
重庆智翔金泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2023-06-20
主营业务：
重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产及商业化。公司的主要产品是赛立奇单抗（GR1501）、斯乐韦米单抗（GR1801）、唯康度塔单抗（GR2001）、泰利奇拜单抗（GR1802）、纬利妥米单抗（GR1803）。截至报告期末，公司已就自身研发的创新成果积极开展知识产权保护，已取得专利授权61项。
发行价格：
37.88
{"stockData":{"symbol":"688443","market":"SH","secType":"STK","nameCN":"智翔金泰-U","latestPrice":24.69,"timestamp":1783666802000,"preClose":23.91,"halted":0,"volume":4947224,"delay":0,"changeRate":0.0326,"floatShares":143000000,"shares":367000000,"eps":-1.5391,"marketStatus":"已收盘","change":0.78,"latestTime":"07-10 15:00:02","open":23.77,"high":25.76,"low":23.3,"amount":123000000,"amplitude":0.1029,"askPrice":24.69,"askSize":1,"bidPrice":24.68,"bidSize":20,"shortable":0,"etf":0,"ttmEps":-1.5391,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783906200000},"marketStatusCode":5,"adr":0,"adjPreClose":23.91,"symbolType":"stock_kcb","openAndCloseTimeList":[[1783647000000,1783654200000],[1783659600000,1783666800000]],"highLimit":26.3,"lowLimit":21.52,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":366680000,"isCdr":false,"pbRate":6.31,"roa":"--","roe":"--","epsLYR":-1.46,"committee":0.245902,"marketValue":9053000000,"turnoverRate":0.0345,"status":0,"afterMarket":{"amount":0,"volume":0,"close":24.69,"buyVolume":1700,"sellVolume":0,"time":1783668837746,"indexStatus":"已收盘 07-10 15:30:00","preClose":23.91},"floatMarketCap":3540000000},"requestUrl":"/m/hq/s/688443/tweets","defaultTab":"tweets","newsList":[{"id":"2649142694","title":"每周股票复盘：智翔金泰（688443）撤回特应性皮炎药注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2649142694","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649142694?lang=zh_cn&edition=full","pubTime":"2026-07-05 02:29","pubTimestamp":1783189750,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘，智翔金泰报收于25.2元，较上周的21.43元上涨17.59%。公司公告汇总自愿披露关于撤回药品注册申请的公告重庆智翔金泰生物制药股份有限公司主动申请撤回泰利奇拜单抗注射液用于成人中、重度特应性皮炎适应症的药品注册申请，并获国家药品监督管理局药品审评中心同意。该撤回不涉及药物安全性与疗效问题，公司将在近期重新提交注册申请。泰利奇拜单抗注射液其他适应症的新药上市申请已获受理或处于不同临床试验阶段。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648511272","title":"智翔金泰（688443）披露关于撤回药品注册申请的公告，7月01日股价上涨4.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648511272","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648511272?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:55","pubTimestamp":1782899713,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘，智翔金泰报收于24.28元，较前一交易日上涨4.43%，最新总市值为89.03亿元。该股当日开盘22.86元，最高24.4元，最低22.02元，成交额达1.81亿元，换手率为5.42%。公司于近日披露《自愿披露关于撤回药品注册申请的公告》。该撤回不涉及药物安全性与疗效问题，公司将在近期重新提交注册申请。泰利奇拜单抗注射液其他适应症的新药上市申请已获受理或处于不同临床试验阶段。本次撤回对公司整体研发、当期生产经营和业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100034856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647345596","title":"股市必读：智翔金泰（688443）6月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2647345596","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647345596?lang=zh_cn&edition=full","pubTime":"2026-06-29 04:22","pubTimestamp":1782678133,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，智翔金泰报收于21.43元，下跌3.34%，换手率3.51%，成交量5.03万手，成交额1.08亿元。董秘最新回复投资者： 董秘，你好，根据我长期跟踪贵司经营情况，我预计贵司2026年半年报业绩将大幅增长，请问贵司是否会主动披露业绩预报？公司唯康度塔单抗注射液、泰利奇拜单抗注射液、纬利妥米单抗注射液的上市申请均处于正常审评阶段，后续进展敬请关注公司公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900001361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645850546","title":"智翔金泰（688443）2671万股限售股将于6月24日解禁，占总股本7.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645850546","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645850546?lang=zh_cn&edition=full","pubTime":"2026-06-24 08:01","pubTimestamp":1782259287,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，智翔金泰于6月24日将有2671.0万股限售股份解禁，为公司首发原股东限售股份，占公司总股本7.28%。本次解禁后，公司还有2.23亿股限售股份，占总股本60.9%。智翔金泰主营业务：抗体药物的研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062400007529.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645073985","title":"智翔金泰（688443）披露斯乐韦米单抗注射液获批上市，6月22日股价下跌2.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073985","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645073985?lang=zh_cn&edition=full","pubTime":"2026-06-22 22:31","pubTimestamp":1782138678,"startTime":"0","endTime":"0","summary":"截至2026年6月22日收盘，智翔金泰报收于21.29元，较前一交易日下跌2.56%，最新总市值为78.07亿元。该股当日开盘21.69元，最高21.8元，最低20.07元，成交额达1.42亿元，换手率为5.88%。近日，重庆智翔金泰生物制药股份有限公司收到国家药品监督管理局核准签发的《药品注册证书》，批准其自主研发的1类新药斯乐韦米单抗注射液上市，用于成人狂犬病病毒暴露者的被动免疫。公司已与康哲药业签署独家合作协议，授予其中国大陆及部分亚太地区的商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200038999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645047633","title":"智翔金泰(688443.SH)：狂犬病被动免疫制剂“斯乐韦米单抗注射液”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645047633","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645047633?lang=zh_cn&edition=full","pubTime":"2026-06-22 16:18","pubTimestamp":1782116326,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰(688443.SH)公告，公司收到国家药品监督管理局核准签发的《药品注册证书》，批准公司自主研发用于成人狂犬病病毒暴露者的被动免疫适应症的1类新药斯乐韦米单抗注射液(商品名：金速希)上市。据悉，斯乐韦米单抗注射液是全球首款针对狂犬病病毒双表位的全人源双特异性抗体，可大规模标准化稳定生产。同时，该产品也是目前剂量最小的狂犬病被动免疫制剂，用量少，易推注，可有效减轻患者疼痛感，提高依从性，分子设计符合WHO推荐的“鸡尾酒式”疗法，其上市有望给患者提供多方位保护。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645015495","title":"股市必读：智翔金泰（688443）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645015495","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645015495?lang=zh_cn&edition=full","pubTime":"2026-06-22 03:32","pubTimestamp":1782070333,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，智翔金泰报收于21.85元，上涨5.0%，换手率5.15%，成交量6.01万手，成交额1.3亿元。董秘最新回复投资者： GR1603临床二期完成已一年多了还没进临床三期，是不是打算放弃开发了？投资者： 截止6月12日，公司尚未收到药友制药应支付3亿元人民币的首付款。交易信息汇总资金流向6月18日主力资金净流出631.32万元，占总成交额0.0%；游资资金净流入568.5万元，占总成交额0.0%；散户资金净流入62.82万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200001227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644065845","title":"每周股票复盘：智翔金泰（688443）部分限售股将上市流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2644065845","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644065845?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:40","pubTimestamp":1781894423,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，智翔金泰报收于21.85元，较上周的22.31元下跌2.06%。本周，智翔金泰6月18日盘中最高价报22.71元。公司公告汇总重庆智翔金泰生物制药股份有限公司首次公开发行部分限售股将于2026年6月24日上市流通，本次解除限售股份数量为26,710,000股，占公司总股本的7.2843%。本次解除限售后，上述股东所持相关限售股份全部上市流通。相关股东已履行限售承诺，保荐机构对本次限售股上市流通无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643753023","title":"智翔金泰（688443）披露首次公开发行部分限售股上市流通公告，6月16日股价下跌2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643753023","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643753023?lang=zh_cn&edition=full","pubTime":"2026-06-16 17:58","pubTimestamp":1781603911,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，智翔金泰报收于21.18元，较前一交易日下跌2.26%，最新总市值为77.66亿元。近日，智翔金泰发布《首次公开发行部分限售股上市流通公告》。公告显示，公司首次公开发行部分限售股将于2026年6月24日上市流通，本次解除限售股份数量为26,710,000股，占公司总股本的7.2843%。本次解除限售后，上述股东所持相关限售股份全部上市流通。公司总股本不变，有限售条件股份减少26,710,000股，无限售条件股份相应增加。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600032454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643653206","title":"智翔金泰2671万股即将解禁 分析师称属正常市场行为","url":"https://stock-news.laohu8.com/highlight/detail?id=2643653206","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643653206?lang=zh_cn&edition=full","pubTime":"2026-06-15 21:04","pubTimestamp":1781528641,"startTime":"0","endTime":"0","summary":"中国网财经6月15日讯 今日晚间，智翔金泰 发布公告称，公司首次公开发行的部分限售股将于2026年6月24日锁定期届满并上市流通。本次解除限售的股份数量为2671万股，占公司总股本的比例约为7.28%。换言之，虽然名义上公司此次可解禁2671万股，但实际上可减持的股票数量仅为2671万股的25%，即667.75万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260615/32280294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127602","title":"每周股票复盘：智翔金泰（688443）2025年度股东会审议通过多项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127602","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127602?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:33","pubTimestamp":1780770790,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘，智翔金泰报收于22.51元，较上周的26.8元下跌16.01%。公司公告汇总北京市万商天勤律师事务所就重庆智翔金泰生物制药股份有限公司2025年年度股东会的召集、召开程序、出席会议人员资格、召集人资格及表决程序、表决结果等事项出具法律意见书。重庆智翔金泰生物制药股份有限公司于2026年6月1日召开2025年年度股东会，会议由董事会召集，董事长刘志刚主持，采用现场与网络投票相结合方式召开。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639960129","title":"每周股票复盘：智翔金泰（688443）GR1803项目获3亿首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2639960129","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639960129?lang=zh_cn&edition=full","pubTime":"2026-05-31 02:08","pubTimestamp":1780164492,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，智翔金泰报收于26.8元，较上周的29.75元下跌9.92%。本周，智翔金泰5月25日盘中最高价报31.6元。本周关注点公司公告汇总：智翔金泰与药友制药签署GR1803项目许可协议，首付款达30,000万元。公司公告汇总：公司及子公司拟申请2026年度不超过29亿元综合授信额度。GR1803注射液目前处于新药上市申请审评阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100000462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638944986","title":"智翔金泰（688443）披露GR1803项目许可协议，5月28日股价下跌0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638944986","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638944986?lang=zh_cn&edition=full","pubTime":"2026-05-28 22:58","pubTimestamp":1779980293,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘，智翔金泰报收于29.51元，较前一交易日下跌0.81%，最新总市值为108.21亿元。该股当日开盘29.78元，最高30.65元，最低29.23元，成交额达1.07亿元，换手率为3.09%。近日，重庆智翔金泰生物制药股份有限公司与重庆药友制药有限责任公司就GR1803项目签署许可协议。药友制药获得GR1803注射液在中国大陆及港澳台地区的开发、生产、商业化独占权利。协议自双方签署后生效，履行期限至销售提成期限届满之日。GR1803注射液目前处于新药上市申请审评阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800043666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693315","title":"A股公告精选 | 中芯国际(00981)、沪硅产业(688126.SH)等近期遭国家大基金减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693315","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638693315?lang=zh_cn&edition=full","pubTime":"2026-05-28 20:14","pubTimestamp":1779970451,"startTime":"0","endTime":"0","summary":"据港交所文件披露，国家集成电路产业投资基金股份有限公司对中芯国际的多头持仓比例于2026年5月26日从8.08%降至7.99%。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260528/20260528201402_31661.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260528/20260528201402_31661.png?x-oss-process=image/format,jpg/quality,q_60&image_source=0"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447358.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0229","LU2476274308.USD","BK0006","BK0064","BK0187","BK1610","LU1997245177.USD","LU2778985437.USD","BK0071","BK0177","00981","688373","000691","BK0280","01055","BK0152","LU1997245094.SGD","LU2495084118.USD","600330","BK0084","BK1607","688981","LU1719994722.HKD","BK0028","688008","BK0061","688443","BK0102","BK0196","BK0242","LU0456842615.SGD","601958","BK0231","LU1251922891.USD","BK1526","LU1997244956.HKD","BK0188","BK0214","300941","06809","BK0164","LU1303224171.USD","BK0259","LU1770034418.SGD","LU2039709279.SGD","LU2289578879.USD","603011","BK1614","BK0070","600029","BK0183","BK0022","BK0182","BK0012","BK1163","BK0077","LU2476274720.SGD","BK0000","BK0139","BK0010","688126","BK0076","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109707509","title":"复星医药子公司药友制药与智翔金泰签署许可协议，潜在首付款及里程碑付款总额高达6亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109707509","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109707509?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:34","pubTimestamp":1779960896,"startTime":"0","endTime":"0","summary":"复星医药宣布，其控股子公司重庆药友制药有限责任公司已与重庆智翔金泰生物制药股份有限公司签署了一项独家许可协议。根据协议条款，药友制药将获得智翔金泰一款在研创新药物在中国大陆地区的独家商业化权益。\n此次合作涉及的首付款及潜在的开发、注册和销售里程碑付款总额最高可达人民币6亿元。此外，在协议产品上市销售后，智翔金泰还将有权获得基于净销售额的阶梯分成。这一战略合作旨在结合药友制药强大的商业化能力与智翔金泰的研发实力，共同推进创新疗法的市场准入，惠及广大患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0188","688443","BK0196","BK0096","BK0239","BK0060","600196","BK0183","BK0187","BK0175","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176557652","title":"复星医药宣布智翔金泰授予药友集团抗体药物产品大中华区独家开发、商业化及生产权","url":"https://stock-news.laohu8.com/highlight/detail?id=1176557652","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176557652?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:34","pubTimestamp":1779960872,"startTime":"0","endTime":"0","summary":"上海复星医药（集团）股份有限公司宣布，其关联公司重庆智翔金泰生物制药股份有限公司已授予上海药友制药有限公司一项抗体药物产品在大中华区（包括中国大陆、香港、澳门及台湾地区）的独家开发、商业化及生产权利。\n此次授权协议涵盖了该抗体药物的全面权益，标志着相关方在生物医药领域战略合作的重要一步。通过整合智翔金泰的研发实力与药友集团的商业化及生产能力，各方旨在加速该创新疗法在大中华区的开发进程，并最终惠及广大患者。这一合作也体现了中国生物医药产业生态内部分工协作、优势互补的积极趋势。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0196","BK0187","BK0060","688443","BK0175","BK0012","BK0183","BK0188","BK0239","600196","BK0096","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638671666","title":"智翔金泰(688443.SH)与药友制药就GR1803项目签署许可协议 总金额至高18.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2638671666","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638671666?lang=zh_cn&edition=full","pubTime":"2026-05-28 16:50","pubTimestamp":1779958206,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰 发布公告，2026年5月28日，公司与上海复星医药(集团)股份有限公司之控股公司重庆药友制药有限责任公司就GR1803项目签署许可协议。根据协议，药友制药将获得GR1803注射液在许可区域及领域的开发、生产、商业化权益。协议的签订将有助于快速推进GR1803注射液在中国市场的开发、注册及商业化进程，若进展顺利，将对公司未来业绩产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447135.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688443","01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636062738","title":"每周股票复盘：智翔金泰（688443）GR1803获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636062738","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636062738?lang=zh_cn&edition=full","pubTime":"2026-05-17 05:00","pubTimestamp":1778965237,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘，智翔金泰报收于30.05元，较上周的30.77元下跌2.34%。本周，智翔金泰5月12日盘中最高价报31.81元。自愿披露关于GR1803注射液获得药物临床试验批准通知书的公告重庆智翔金泰生物制药股份有限公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，其自主研发的GR1803注射液获准在复发性/难治性多发性骨髓瘤患者中开展临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051700001680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635619718","title":"智翔金泰(688443.SH)在研产品GR1803注射液(皮下注射)临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2635619718","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635619718?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:37","pubTimestamp":1778751467,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司在研产品GR1803注射液临床试验申请获得批准。公告显示，GR1803注射液是一款由公司自主研发的双特异性抗体药物，作用靶点为BCMA和CD3，注册分类为治疗用生物制品1类。本次将GR1803注射液的给药方式拓展为皮下注射，可提高患者的用药便利性与依从性，减少就诊耗时及医疗资源占用。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"智翔金泰(688443.SH)在研产品GR1803注射液(皮下注射)临床试验申请获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635173594","title":"智翔金泰（688443）披露召开2025年年度暨2026年第一季度业绩说明会公告，5月13日股价下跌1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635173594","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635173594?lang=zh_cn&edition=full","pubTime":"2026-05-13 22:45","pubTimestamp":1778683518,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，智翔金泰报收于30.85元，较前一交易日下跌1.12%，最新总市值为113.12亿元。该股当日开盘31.15元，最高31.42元，最低29.85元，成交额达1.37亿元，换手率为3.84%。近日，重庆智翔金泰生物制药股份有限公司发布《关于召开2025年年度暨2026年第一季度业绩说明会的公告》。公告显示，公司将于2026年5月22日15:00-16:00通过网络互动方式在“价值在线”平台召开业绩说明会，介绍公司2025年年度及2026年第一季度经营业绩和发展战略。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300045947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783673202412,"stockEarnings":[{"period":"1week","weight":-0.0008},{"period":"1month","weight":0.1069},{"period":"3month","weight":-0.2009},{"period":"6month","weight":-0.2629},{"period":"1year","weight":-0.1557},{"period":"ytd","weight":-0.1222}],"compareEarnings":[{"period":"1week","weight":0.0019},{"period":"1month","weight":0.0066},{"period":"3month","weight":0.0126},{"period":"6month","weight":-0.0203},{"period":"1year","weight":0.1556},{"period":"ytd","weight":0.0171}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智翔金泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12843人(较上一季度增加1.70%)","perCapita":"11164股","listingDate":"2023-06-20","address":"重庆市巴南区麻柳大道699号2号楼A区","registeredCapital":"36668万元","survey":" 重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产及商业化。公司的主要产品是赛立奇单抗（GR1501）、斯乐韦米单抗（GR1801）、唯康度塔单抗（GR2001）、泰利奇拜单抗（GR1802）、纬利妥米单抗（GR1803）。截至报告期末，公司已就自身研发的创新成果积极开展知识产权保护，已取得专利授权61项。","listedPrice":37.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智翔金泰-U(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智翔金泰-U(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智翔金泰-U,688443,智翔金泰-U股票,智翔金泰-U股票老虎,智翔金泰-U股票老虎国际,智翔金泰-U行情,智翔金泰-U股票行情,智翔金泰-U股价,智翔金泰-U股市,智翔金泰-U股票价格,智翔金泰-U股票交易,智翔金泰-U股票购买,智翔金泰-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智翔金泰-U(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智翔金泰-U(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}